TScan Therapeutics, Inc. (TCRX)
Nasdaq · Healthcare · Biotechnology
$0.2953−7.86%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $20.0M
- 52-week range
- $0.285 – $2.57
- 52-week change
- −83.71%
- EPS (trailing)
- −$0.85
- Analyst rating
- 2.6 Hold
Fiscal year to Dec 2025
- Revenue
- $10.3M (+266.65%)
- Net income
- −$130M
- Operating margin
- −1315.4%
- Diluted EPS
- −$1.00
- Free cash flow
- −$140M
From the company’s annual report on SEC EDGAR.
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Headquarters: Waltham, United States · 138 employees · tscan.com